Salix’s Once-Daily APRISO Demonstrates Long-Term Safety In Patients For Maintenance Of Remission From Ulcerative Colitis

Data was announced today that demonstrated Salix Pharmaceuticals’ (NASDAQ:SLXP) APRISO? (mesalamine) 0.375g extended-release capsules had a favorable safety profile in patients in remission from ulcerative colitis (UC) for up to 24 months. APRISO is approved for use up to six months. The majority of treatment-emergent adverse events were mild or moderate in intensity, and were similar to what was seen during the 6-month phase 3 trials.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on June 5th, 2009